Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06799533 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT06799533 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 11 participants.
The verdict
NCT06799533, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study will test the safety of a drug called PF-08046031 in participants with melanoma and other solid tumors that have no current approved treatment or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. The study will have 3 parts. Part A and B of the study will find out how much PF-08046031 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046031 is safe and if it works to treat solid tumor cancers.
Interventions
- DRUG PF-08046031
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2026-02-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06799533
The ClinicalTrials.gov registry entry for NCT06799533 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-08046031 is the first listed.
NCT06799533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06799533 about?
NCT06799533 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors". This study will test the safety of a drug called PF-08046031 in participants with melanoma and other solid tumors that have no current approved treatment or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treat...
What is the current status of trial NCT06799533?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2025-05-01. Estimated completion is 2026-02-23.
What interventions are being tested in trial NCT06799533?
The interventions under investigation include: PF-08046031 (DRUG).
Who is sponsoring clinical trial NCT06799533?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.